SCHEMBL1193595

SCHEMBL1193595

CC(=O)Oc1ccccc1C(=O)Oc1c(C)occc1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.54
KDM4E B2RXH2 3/20 0.54
LMNA P02545 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP2C9 P11712 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
PTGS2 P35354 5/20 0.48
TSHR P16473 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
ESR1 P03372 1/20 0.48
ITGB3 P05106 1/20 0.48
ITGA2B P08514 1/20 0.48
HMGB1 P09429 1/20 0.48
HPGD P15428 1/20 0.48
GGT1 P19440 1/20 0.48
PTGS1 P23219 1/20 0.48
BLM P54132 1/20 0.48
NAPRT Q6XQN6 1/20 0.48
KMT2A Q03164 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31113422 1.00 HSD17B10 (0.54) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL1193101 0.86 KDM4E (0.49) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL9516082 0.82 SMN1; SMN2 (0.52) HSD17B10KDM4ELMNASMN1; SMN2TSHR
SCHEMBL31113429 0.82 SMN1; SMN2 (0.52) HSD17B10KDM4ELMNASMN1; SMN2TSHR
SCHEMBL1845901 0.81 SMN1; SMN2 (0.55) HSD17B10KDM4ELMNASMN1; SMN2ALDH1A1
Aspirin SCHEMBL9426063 0.78 KDM4E (0.61) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL9721396 0.77 SMN1; SMN2 (0.63) KDM4ELMNASMN1; SMN2ALDH1A1TDP1
SCHEMBL21449134 0.73 PTGS2 (0.68) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL27969404 0.72 HSD17B10 (0.67) HSD17B10KDM4ELMNACYP1A2CYP2C9
SCHEMBL5988737 0.71 HSD17B10 (0.71) HSD17B10KDM4ELMNACYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP claimed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO claimed
US-20120328696-A1 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER HUTECS KOREA PHARMACEUTICAL CO., LTD. (KR) 2012-12-27 US claimed
US-20110039807-A1 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER HUTECS KOREA PHARMACEUTICAL CO. LTD (KR) 2011-02-17 US claimed
WO-2010020920-A2 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER KANGWON NATIONAL UNIVERSITY (KR) 2010-02-25 WO claimed
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US disclosed
CN-119833201-A Conductive silver paste, method for preparing back electrode of solar cell and solar cell 乐凯胶片股份有限公司 2025-04-15 CN disclosed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP disclosed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO disclosed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO disclosed
US-11645676-B2 Extending audience reach in messaging campaigns using probabilistic ID linking ORACLE INTERNATIONAL CORPORATION (US) 2023-05-09 US disclosed
US-20120328696-A1 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER HUTECS KOREA PHARMACEUTICAL CO., LTD. (KR) 2012-12-27 US disclosed
WO-2010020920-A3 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER KANGWON NATIONAL UNIVERSITY (KR) 2010-06-03 WO disclosed
WO-2010020920-A2 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER KANGWON NATIONAL UNIVERSITY (KR) 2010-02-25 WO disclosed
WO-2010020920-A2 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER KANGWON NATIONAL UNIVERSITY (KR) 2010-02-25 WO disclosed
WO-2010020920-A2 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER KANGWON NATIONAL UNIVERSITY (KR) 2010-02-25 WO disclosed
EP-0544681-B1 A NOVEL SALICYLIC ACID-MALTOL CONJUGATES HAN BYUNG HOON (KR) 1997-02-12 EP disclosed
US-5349070-A Side effect reduction of ulcers; antioxidants, anticoagulants HAN BYUNG H (KR) 1994-09-20 US disclosed
EP-0544681-A1 A NOVEL SALICYLIC ACID-MALTOL CONJUGATES. HAN BYUNG HOON (KR) 1993-06-09 EP disclosed
WO-1993000339-A1 A NOVEL SALICYLIC ACID-MALTOL CONJUGATES HAN BYUNG HOON (KR) 1993-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039807-A1 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER SNCA, PARK7, MGAM HSD17B10 1296/4885KDM4E 3957/4885LMNA 3806/4885
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS NOD2, PYCARD, CLPP HSD17B10 1696/4885KDM4E 4332/4885LMNA 2204/4885
US-20120328696-A1 ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER SNCA, PARK7, MGAM HSD17B10 1296/4885KDM4E 3957/4885LMNA 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.